Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Lowered to Buy at StockNews.com

StockNews.com lowered shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a strong-buy rating to a buy rating in a research note published on Saturday morning.

REGN has been the subject of a number of other reports. Cantor Fitzgerald reaffirmed a neutral rating and set a $925.00 price target on shares of Regeneron Pharmaceuticals in a research note on Monday, April 15th. Bank of America raised their price objective on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an underperform rating in a research note on Friday, April 12th. Barclays raised their price objective on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an overweight rating in a research note on Tuesday, January 23rd. Truist Financial reissued a buy rating and set a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. Finally, Royal Bank of Canada reissued an outperform rating and set a $1,189.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 9th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of Moderate Buy and a consensus price target of $976.41.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $907.32 on Friday. The business has a 50 day simple moving average of $951.41 and a 200 day simple moving average of $893.20. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. The firm has a market capitalization of $99.59 billion, a price-to-earnings ratio of 26.11, a price-to-earnings-growth ratio of 2.58 and a beta of 0.11. Regeneron Pharmaceuticals has a 12-month low of $684.80 and a 12-month high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. The firm had revenue of $3.43 billion during the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The firm’s quarterly revenue was up .6% on a year-over-year basis. During the same period last year, the company posted $10.96 EPS. On average, equities research analysts anticipate that Regeneron Pharmaceuticals will post 38.8 EPS for the current year.

Insider Activity at Regeneron Pharmaceuticals

In related news, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares of the company’s stock, valued at $46,203,239.82. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $982.05, for a total value of $98,205.00. Following the completion of the sale, the director now owns 18,282 shares of the company’s stock, valued at $17,953,838.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Andrew J. Murphy sold 5,783 shares of the business’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the sale, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 11,022 shares of company stock valued at $10,552,991. Insiders own 8.83% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC increased its stake in shares of Regeneron Pharmaceuticals by 7.3% in the third quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock worth $8,098,661,000 after purchasing an additional 669,517 shares during the period. Vanguard Group Inc. increased its stake in shares of Regeneron Pharmaceuticals by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 8,838,285 shares of the biopharmaceutical company’s stock worth $7,762,577,000 after purchasing an additional 39,780 shares during the period. Capital World Investors increased its stake in shares of Regeneron Pharmaceuticals by 0.5% in the fourth quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock worth $4,506,071,000 after purchasing an additional 23,146 shares during the period. Putnam Investments LLC increased its stake in shares of Regeneron Pharmaceuticals by 2.1% in the fourth quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock worth $1,063,377,000 after purchasing an additional 24,329 shares during the period. Finally, Northern Trust Corp increased its stake in shares of Regeneron Pharmaceuticals by 3.3% in the third quarter. Northern Trust Corp now owns 1,067,210 shares of the biopharmaceutical company’s stock worth $878,271,000 after purchasing an additional 34,326 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.